Additionally, the presence of ctDNA postoperatively was predictive of recurrence. This study corroborates current literature and provides rational for moving toward a clinical trial using ctDNA and dPCR to detect MRD after CRLM resection.

1 year ago

Journal • Minimal residual disease • Circulating tumor DNA

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

KRAS mutation • PIK3CA mutation • PIK3CA mutation + KRAS mutation

over1year

Association between KRAS and PIK3CA Mutations and Progesterone Resistance in Endometriotic Epithelial Cell Line. (PubMed, Curr Issues Mol Biol)

We conducted a migration assay, invasion assay, and MTT assay using dienogest and medroxyprogestrone acetate. Our results suggest that KRAS mutation and PIK3CA mutation in endometriotic cells may not be associated with progesterone resistance in terms of aggressiveness. However, KRAS mutations may be associated with progesterone resistance in the context of pain.

over 1 year ago

Preclinical • Journal

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • IL6 (Interleukin 6)

KRAS mutation • PIK3CA mutation • PGR expression • PIK3CA mutation + KRAS mutation

2years

Mixed Mesonephric-like Adenocarcinoma, Clear Cell Carcinoma, and Endometrioid Carcinoma Arising from an Endometriotic Cyst. (PubMed, Int J Surg Pathol)

To the best of our knowledge, this is the first report of mesonephric-like adenocarcinoma combined with a clear cell carcinoma and endometrioid carcinoma, which supports the hypothesis that mesonephric-like adenocarcinoma is an endometriosis-associated neoplasm. The report also highlights a potential pitfall in diagnosing mesonephric-like adenocarcinoma combined with clear cell carcinoma.

2 years ago

Journal

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • ARID1A (AT-rich interaction domain 1A) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8)

KRAS mutation • PIK3CA mutation • ARID1A mutation • PIK3CA mutation + KRAS mutation

2years

Title , Early Identification of KRAS and PIK3CA Mutations Using Multiplex Digital PCR Compatible with Liquid Biopsy Samples to Support Tumor Progression Surveillance (AMP 2023)

We developed a comprehensive multiplex mutant detection method with high sensitivity and specificity. This study demonstrates the strong potential of Absolute Q dPCR as a powerful multiplex platform for early mutation detection and monitoring in liquid biopsy samples.

2 years ago

Liquid biopsy • Biopsy

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

KRAS mutation • KRAS G12C • PIK3CA mutation • KRAS G12D • PIK3CA H1047R • KRAS wild-type • PIK3CA E545K • RAS wild-type • KRAS G12 • PIK3CA E542K • KRAS G12S • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA mutation + KRAS mutation

over2years

Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience. (PubMed, Indian J Pathol Microbiol)

Although no statistical significance was found between the detected mutation and clinicopathological data, it was concluded that PDGFRA mutation might be associated with advanced-stage disease development. This study's findings regarding different molecular types of UCS and information on oncogenesis of UCS can provide inferences for targeted therapies in the future by identifying targetable mutations representing early oncogenic events and thereby contribute toward further studies on this subject.

over 2 years ago

Journal • Next-generation sequencing

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)

KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • KIT mutation • PDGFRA mutation • EGFR mutation + PIK3CA mutation • PIK3CA mutation + KRAS mutation

over2years

KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. (PubMed, Crit Rev Oncol Hematol)

The backbone of common KRAS and PIK3CA mutations is a rational frame for development of therapeutic algorithms in colorectal cancer and can help guide new drug therapies development. In addition, the prevalence of different molecular groups presented here may help with planning of combination clinical trials by providing estimations of sub-sets with more than one alteration.

over 2 years ago

Review • Journal • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A)

KRAS mutation • BRAF mutation • PIK3CA mutation • ATM mutation • ARID1A mutation • KRAS wild-type • RAS wild-type • PIK3CA wild-type • PIK3CA mutation + KRAS mutation • KRAS mutation + PIK3CA wild-type • PIK3CA mutation + RAS wild-type

over2years

Comparative genomic proﬁling and disease monitoring in unresectable gastric and colon cancer (AACR 2023)

"This study compared the variation landscape between gastric and colon cancer patients, and demonstrated the technical feasibility of genome-wide copy number variations through liquid biopsy, revealing its potential clinical utility of longitudinal disease monitoring."

over 2 years ago

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden)

KRAS mutation • PIK3CA mutation • PIK3CA mutation + KRAS mutation

PredicineATLAS™ • PredicineCNB™

almost3years

Molecular Landscape and Association With Crohn Disease of Poorly Cohesive Carcinomas of the Nonampullary Small Bowel. (PubMed, Am J Clin Pathol)

SB-PCCs may harbor RHOA mutations, which are reminiscent of the diffuse subtype of gastric cancers or appendiceal GCAs, while KRAS and PIK3CA mutations, commonly involved in colorectal and small bowel adenocarcinomas, are not typical of such cancers.

almost 3 years ago

Journal • MSi-H Biomarker

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • RHOA (Ras homolog family member A)

KRAS mutation • MSI-H/dMMR • BRAF mutation • HER-2 amplification • PIK3CA mutation • IDH1 mutation • FGFR2 mutation • FGFR2 amplification • KRAS amplification • PIK3CA mutation + KRAS mutation • BRAF amplification

TruSight Oncology 500 Assay

almost3years

Establishment of a Novel In Vitro Model of Endometriosis with Oncogenic KRAS and PIK3CA Mutations (WCE 2023)

Patient-derived organoids are potentially a useful platform to explore molecular pathogenesis of endometriosis and ovarian cancer from endometriosis and discover personalized drugs. Our experimental system and associated datasets of WES and RNA-seq are expected to have broad applications in studying biology of the human endometriosis.

almost 3 years ago

Preclinical

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A)

KRAS mutation • PIK3CA mutation • PIK3CA mutation + KRAS mutation

3years

KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania. (PubMed, Medicine (Baltimore))

In conclusion, the assessment of these mutations suggests that CRC patients from southeast Romania exhibit a mutation profile similar to other populations. These results could contribute to creating a better method of qualifying patients for molecularly targeted therapies and obtaining better screening strategies.

3 years ago

Journal • MSi-H Biomarker

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)

KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • NRAS mutation • PIK3CA mutation • KRAS exon 2 mutation • AKT1 mutation • PIK3CA mutation + KRAS mutation • BRAF exon 15 mutation

over3years

Histomorphological and molecular genetic characterization of different intratumoral regions and matched metastatic lymph nodes of colorectal cancer with heterogenous mismatch repair protein expression. (PubMed, J Cancer Res Clin Oncol)

Intratumoral heterogeneous MSI status is highly correlated with intratumoral histomorphological heterogeneity, which is also an important clue for the intratumoral heterogeneity of drive gene mutations in CRC. Thus, it is essential to detect MMR protein expression and other gene mutations in metastases before treatment, especially for CRCs with intratumoral heterogenous MMR protein expression or heterogenous histomorphological features.

over 3 years ago

Journal • Mismatch repair • MSi-H Biomarker

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)

KRAS mutation • MSI-H/dMMR • PIK3CA mutation • PIK3CA mutation + KRAS mutation

over3years

Mesonephric-Like Adenocarcinoma of Uterine Corpus: A Clinicopathological and Targeted Genomic Profiling Study in a Single Institution. (PubMed, Front Oncol)

MLA is a rare and aggressive malignancy, representing approximately 1% of all endometrial carcinomas. It exhibits mixed architectures associated with distinctive immunophenotype and recurrent KRAS and PIK3CA mutations, supporting classified as of Müllerian origin with mesonephric differentiation.

over 3 years ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • NKX2-1 (NK2 Homeobox 1) • MME (Membrane Metalloendopeptidase) • GATA3 (GATA binding protein 3)

TP53 mutation • KRAS mutation • PIK3CA mutation • PTEN mutation • ARID1A mutation • TP53 expression • PGR expression • PIK3CA mutation + KRAS mutation